233 related articles for article (PubMed ID: 23318419)
1. Soluble E-cadherin: a critical oncogene modulating receptor tyrosine kinases, MAPK and PI3K/Akt/mTOR signaling.
Brouxhon SM; Kyrkanides S; Teng X; Athar M; Ghazizadeh S; Simon M; O'Banion MK; Ma L
Oncogene; 2014 Jan; 33(2):225-35. PubMed ID: 23318419
[TBL] [Abstract][Full Text] [Related]
2. Ectodomain-specific E-cadherin antibody suppresses skin SCC growth and reduces tumor grade: a multitargeted therapy modulating RTKs and the PTEN-p53-MDM2 axis.
Brouxhon SM; Kyrkanides S; Raja V; Silberfeld A; Teng X; Trochesset D; Cohen J; Ma L
Mol Cancer Ther; 2014 Jul; 13(7):1791-802. PubMed ID: 24748654
[TBL] [Abstract][Full Text] [Related]
3. Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers.
Brouxhon SM; Kyrkanides S; Teng X; O'Banion MK; Clarke R; Byers S; Ma L
Mol Carcinog; 2014 Nov; 53(11):893-906. PubMed ID: 23776059
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells.
Lau MT; So WK; Leung PC
PLoS One; 2013; 8(3):e59083. PubMed ID: 23554977
[TBL] [Abstract][Full Text] [Related]
5. Formation of E-cadherin-mediated cell-cell adhesion activates AKT and mitogen activated protein kinase via phosphatidylinositol 3 kinase and ligand-independent activation of epidermal growth factor receptor in ovarian cancer cells.
Reddy P; Liu L; Ren C; Lindgren P; Boman K; Shen Y; Lundin E; Ottander U; Rytinki M; Liu K
Mol Endocrinol; 2005 Oct; 19(10):2564-78. PubMed ID: 15928314
[TBL] [Abstract][Full Text] [Related]
6. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of T-cadherin inhibits the proliferation of oral squamous cell carcinoma through the PI3K/AKT/mTOR intracellular signalling pathway.
Wang Q; Zhang X; Song X; Zhang L
Arch Oral Biol; 2018 Dec; 96():74-79. PubMed ID: 30195142
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody against the ectodomain of E-cadherin (DECMA-1) suppresses breast carcinogenesis: involvement of the HER/PI3K/Akt/mTOR and IAP pathways.
Brouxhon SM; Kyrkanides S; Teng X; Raja V; O'Banion MK; Clarke R; Byers S; Silberfeld A; Tornos C; Ma L
Clin Cancer Res; 2013 Jun; 19(12):3234-46. PubMed ID: 23620408
[TBL] [Abstract][Full Text] [Related]
9. Modulation of RTK by sEcad: a putative mechanism for oncogenicity in oropharyngeal SCCs.
Teng X; Ma L; Kyrkanides S; Raja V; Trochesset D; Brouxhon SM
Oral Dis; 2015 Mar; 21(2):185-94. PubMed ID: 24612046
[TBL] [Abstract][Full Text] [Related]
10. Independent and cooperative roles of the Mek/ERK1/2-MAPK and PI3K/Akt/mTOR pathways during developmental myelination and in adulthood.
Ishii A; Furusho M; Macklin W; Bansal R
Glia; 2019 Jul; 67(7):1277-1295. PubMed ID: 30761608
[TBL] [Abstract][Full Text] [Related]
11. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin.
Zuo JH; Zhu W; Li MY; Li XH; Yi H; Zeng GQ; Wan XX; He QY; Li JH; Qu JQ; Chen Y; Xiao ZQ
J Cell Biochem; 2011 Sep; 112(9):2508-17. PubMed ID: 21557297
[TBL] [Abstract][Full Text] [Related]
12. Honokiol induces autophagy of neuroblastoma cells through activating the PI3K/Akt/mTOR and endoplasmic reticular stress/ERK1/2 signaling pathways and suppressing cell migration.
Yeh PS; Wang W; Chang YA; Lin CJ; Wang JJ; Chen RM
Cancer Lett; 2016 Jan; 370(1):66-77. PubMed ID: 26454217
[TBL] [Abstract][Full Text] [Related]
13. Visfatin stimulates endometrial cancer cell proliferation via activation of PI3K/Akt and MAPK/ERK1/2 signalling pathways.
Wang Y; Gao C; Zhang Y; Gao J; Teng F; Tian W; Yang W; Yan Y; Xue F
Gynecol Oncol; 2016 Oct; 143(1):168-178. PubMed ID: 27473926
[TBL] [Abstract][Full Text] [Related]
14. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling.
Zhang D; Brodt P
Oncogene; 2003 Feb; 22(7):974-82. PubMed ID: 12592384
[TBL] [Abstract][Full Text] [Related]
15. NAD(P)H Quinone Dehydrogenase 1 Ablation Inhibits Activation of the Phosphoinositide 3-Kinase/Akt Serine/Threonine Kinase and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Pathways and Blocks Metabolic Adaptation in Hepatocellular Carcinoma.
Dimri M; Humphries A; Laknaur A; Elattar S; Lee TJ; Sharma A; Kolhe R; Satyanarayana A
Hepatology; 2020 Feb; 71(2):549-568. PubMed ID: 31215069
[TBL] [Abstract][Full Text] [Related]
16. Proteinase suppression by E-cadherin-mediated cell-cell attachment in premalignant oral keratinocytes.
Munshi HG; Ghosh S; Mukhopadhyay S; Wu YI; Sen R; Green KJ; Stack MS
J Biol Chem; 2002 Oct; 277(41):38159-67. PubMed ID: 12138162
[TBL] [Abstract][Full Text] [Related]
17. EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.
Martín-Orozco RM; Almaraz-Pro C; Rodríguez-Ubreva FJ; Cortés MA; Ropero S; Colomer R; López-Ruiz P; Colás B
Neoplasia; 2007 Aug; 9(8):614-24. PubMed ID: 17898861
[TBL] [Abstract][Full Text] [Related]
18. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
Shi Y; Yan H; Frost P; Gera J; Lichtenstein A
Mol Cancer Ther; 2005 Oct; 4(10):1533-40. PubMed ID: 16227402
[TBL] [Abstract][Full Text] [Related]
19. The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells.
Lau MT; Leung PC
Cancer Lett; 2012 Dec; 326(2):191-8. PubMed ID: 22922215
[TBL] [Abstract][Full Text] [Related]
20. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
